Dean Leverett
Research Subjects
Dean Leverett has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Graham Merrington
WCA Environment, Faringdon, UK
2 shared publicationsIain Wilson
WCA Environment, Faringdon, UK
2 shared publicationsMark Crane
AG-HERA, Faringdon, UK
2 shared publications- David Taylor
Department of Geography, National University of Singapore
1 shared publication - Graham Merrington
WCA Environment Faringdon Oxfordshire UK
1 shared publication Jim Ryan
GSK, Ware, Hertfordshire, UK
1 shared publication
Latest Publications
- Open Access
- 15 December 2022
- Published by Springer Nature in Environmental Sciences Europe
- Vol. 34 (1) , 1-5
Response to commentary article on environmental quality standards for diclofenac derived under the European water framework directive: 1. Aquatic organisms, by Maack et al. 2022
- 15 December 2022
- Published by Springer Nature in Environmental Sciences Europe
- Vol. 34 (1) , 1-5
Open AccessResponse to commentary article on environmental quality standards for diclofenac derived under the European water framework directive: 1. Aquatic organisms, by Maack et al. 2022
- Open Access
- 5 December 2021
- Published by Springer Nature in Environmental Sciences Europe
- Vol. 33 (1) , 1-11
Environmental quality standards for diclofenac derived under the European Water Framework Directive: 1. Aquatic organisms
Diclofenac is a nonsteroidal anti-inflammatory human and veterinary medicine widely detected in European surface waters, especially downstream from Wastewater Treatment Plants (WWTPs). Veterinary uses of diclofenac in Europe are greatly restricted, so wastewater is the key exposure route for wildlife. Proposed Environmental Quality Standards (EQS) which include an assessment of toxicity to aquatic organisms are under consideration by the European Commission (EC) to support the aims of the Water Framework Directive (WFD). The EC approach favours the use of a deterministic (single test value and an assessment factor) approach to the derivation of a direct toxicity EQS for diclofenac, resulting in an EQS of 0.040 µg L−1 based on a single mesocosm study. In this paper, we discuss potential issues with this approach with respect to the EC’s own guidance on EQS derivation and derive an evidence-driven alternative EQS of 0.126 µg L−1 using a probabilistic (species sensitivity distribution) approach that accounts for all of the reliable and relevant data and is in accordance with the guidance. Europe-wide freshwater monitoring data for diclofenac are used in an indicative compliance assessment using the EC and the alternative evidence-driven EQS. The implications of using only some data to derive an EQS that does not adhere to the guidance, compared to a guidance-compliant approach that uses all the data available are also discussed.
- 5 December 2021
- Published by Springer Nature in Environmental Sciences Europe
- Vol. 33 (1) , 1-11
Open AccessEnvironmental quality standards for diclofenac derived under the European Water Framework Directive: 1. Aquatic organisms
Diclofenac is a nonsteroidal anti-inflammatory human and veterinary medicine widely detected in European surface waters, especially downstream from Wastewater Treatment Plants (WWTPs). Veterinary uses of diclofenac in Europe are greatly restricted, so wastewater is the key exposure route for wildlife. Proposed Environmental Quality Standards (EQS) which include an assessment of toxicity to aquatic organisms are under consideration by the European Commission (EC) to support the aims of the Water Framework Directive (WFD). The EC approach favours the use of a deterministic (single test value and an assessment factor) approach to the derivation of a direct toxicity EQS for diclofenac, resulting in an EQS of 0.040 µg L−1 based on a single mesocosm study. In this paper, we discuss potential issues with this approach with respect to the EC’s own guidance on EQS derivation and derive an evidence-driven alternative EQS of 0.126 µg L−1 using a probabilistic (species sensitivity distribution) approach that accounts for all of the reliable and relevant data and is in accordance with the guidance. Europe-wide freshwater monitoring data for diclofenac are used in an indicative compliance assessment using the EC and the alternative evidence-driven EQS. The implications of using only some data to derive an EQS that does not adhere to the guidance, compared to a guidance-compliant approach that uses all the data available are also discussed.
- Retracted
- 1 October 2015
- Published by Oxford University Press (OUP) in Integrated Environmental Assessment and Management
- Vol. 12 (1) , 209
Retraction: Environmental risk assessment of human pharmaceuticals: Regulatory developments
This article was published online on 1 October 2015, on Wiley Online Library (wileyonlinelibrary.com). The article has been withdrawn by agreement between the authors, the journal Editor-in-Chief, the Society of Environmental Toxicology and Chemistry, and Wiley Periodicals, Inc. The authors initiated the withdrawal on their accord after consideration of regulatory analysis and conclusions appearing in the article, which the authors felt required substantial revision to incorporate new and important regulatory developments not addressed in the article. Reference Gross M, Leverett D, Merrington G, Taylor D. Environmental risk assessment of human pharmaceuticals: Regulatory developments. Integr Environ Assess Manag DOI: 10.1002/ieam.1699
- 1 October 2015
- Published by Oxford University Press (OUP) in Integrated Environmental Assessment and Management
- Vol. 12 (1) , 209
RetractedRetraction: Environmental risk assessment of human pharmaceuticals: Regulatory developments
This article was published online on 1 October 2015, on Wiley Online Library (wileyonlinelibrary.com). The article has been withdrawn by agreement between the authors, the journal Editor-in-Chief, the Society of Environmental Toxicology and Chemistry, and Wiley Periodicals, Inc. The authors initiated the withdrawal on their accord after consideration of regulatory analysis and conclusions appearing in the article, which the authors felt required substantial revision to incorporate new and important regulatory developments not addressed in the article. Reference Gross M, Leverett D, Merrington G, Taylor D. Environmental risk assessment of human pharmaceuticals: Regulatory developments. Integr Environ Assess Manag DOI: 10.1002/ieam.1699